TARGET AUDIENCE
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of myelofibrosis (MF).

PURPOSE STATEMENT
By providing information on the latest research developments in the context of expert perspectives, this NCPD activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with myelofibrosis.

LEARNING OBJECTIVES

• Use an understanding of disease biology and natural history to effectively counsel patients diagnosed with MF about their long-term prognosis.
• Analyze how age, performance status, prior therapeutic exposure and other biological and disease-related factors affect the selection and sequencing of approved JAK inhibitors for patients with primary and secondary MF.
• Appraise available research findings informing the safety and efficacy of novel JAK inhibitors for patients with MF and anemia, and understand the rationale for specific treatment recommendations.
• Review available research data with and the current clinical role of novel JAK inhibitors for patients with MF and severe thrombocytopenia.
• Develop supportive care plans to more effectively monitor for, identify and manage side effects and toxicities associated with agents commonly used for MF.
• Increase participation in active research protocols by counseling appropriately selected patients about the biological rationale for and available efficacy and safety data with novel investigational agents and strategies for MF.

ACCREDITATION STATEMENT
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

CREDIT DESIGNATION STATEMENT
Video Program: This educational activity for 1.75 contact hours is provided by RTP during the period of June 2024 to June 2025.

This activity is awarded 1.75 ANCC pharmacotherapeutic contact hours.

ONCC/ILNA CERTIFICATION INFORMATION
The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. To review certification qualifications please visit https://www.researchtopractice.com/Meetings/ONS2024/Myelofibrosis/ILNA.

ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

PRIVACY POLICY 
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. 

FOR SUCCESSFUL COMPLETION
Video Program: This NCPD activity consists of a video component. To receive credit, the participant should review the NCPD information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/ONS2024/MF/Video/NCPD.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Ilene Galinsky, NP
Senior Adult Leukemia Program Research Nurse Practitioner
Dana-Farber Cancer Institute
Boston, Massachusetts

Advisory Committees: AbbVie Inc, Astellas, CTI BioPharma, a Sobi Company, Novartis, Takeda Pharmaceuticals USA Inc; Consulting Agreements: AbbVie Inc, CTI BioPharma, a Sobi Company, Novartis.

Andrew T Kuykendall, MD
Associate Member, Department of Malignant Hematology
Moffitt Cancer Center
Assistant Professor, Department of Oncologic Sciences
University of South Florida
Tampa, Florida

Advisory Committees: AbbVie Inc, Blueprint Medicines, Bristol Myers Squibb, Cogent Biosciences, CTI BioPharma, a Sobi Company, Incyte Corporation, Karyopharm Therapeutics, PharmaEssentia; Consulting Agreements: AbbVie Inc, Karyopharm Therapeutics, MorphoSys; Contracted Research: Blueprint Medicines, Bristol Myers Squibb, Geron, Janssen Biotech Inc, Protagonist Therapeutics, MorphoSys; Data and Safety Monitoring Board/Committee: Geron.

Sara M Tinsley-Vance, PhD, APRN, AOCN
Nurse Practitioner and Researcher
Malignant Hematology
Moffitt Cancer Center
Courtesy Assistant Professor
University of South Florida College of Nursing
Tampa, Florida

Advisory Committees: AbbVie Inc, CTI BioPharma, a Sobi Company, Incyte Corporation, Pfizer Inc; Consulting Agreements: CTI Biopharma, a Sobi Company, Incyte Corporation, Novartis; Speakers Bureaus: Astellas, Bristol Myers Squibb, CTI BioPharma, a Sobi Company, Incyte Corporation, Jazz Pharmaceuticals Inc; Nonrelevant Financial Relationships (Contracted Research): Gulf Coast Community Foundation, National Institutes of Health, Patient-Centered Outcomes Research Institute.

Abdulraheem Yacoub, MD
Professor of Medicine
Division of Hematologic Malignancies and Cellular Therapeutics (HMCT)
Department of Internal Medicine
The University of Kansas Cancer Center
Westwood, Kansas

Consulting Agreements: AbbVie Inc, Acceleron Pharma, Apellis, CTI BioPharma, a Sobi Company, Gilead Sciences Inc, Incyte Corporation, Karyopharm Therapeutics, Notable Labs, Novartis, Pfizer Inc, PharmaEssentia, Protagonist Therapeutics, Servier Pharmaceuticals LLC.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop NCPD activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from CTI Biopharma, a Sobi Company, GSK, and Incyte Corporation.

Release date: June 2024
Expiration date: June 2025

There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.